Cardinal Health Says It Now Exclusively Serves Nearly Half The Cell-And-Gene Therapy Market
CAH stock hits new 52-week high as Cardinal Health beats Q4 earnings, boosts FY27 outlook, and approves a $5B buyback expansion.
Cardinal Health is now the main supplier for almost half of a new medicine market and had really good earnings, which made investors excited about the company's future. When a company does better than expected and leaders say good things are coming, it's a sign people trust the business is on the right track.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.